ClinicalTrials.gg
Enrolling by invitationNCT07734454Updated Sep 23, 2026

Immersive Visual Modulation and Ambient Music Therapy During Transvaginal Ultrasonography in Women With Vaginismus

An interventional study of Standard Care and Immersive Visual Modulation (IVM) in Vaginismus, sponsored by Demet Mutlu. Enrolling by invitation at 1 site in Turkey (Türkiye). Open to female participants aged 20 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-09-23.

Sponsored by Demet Mutlu · Not applicable, Interventional, and Supportive care

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
20 Years to 40 Years
Sex
Female
01

Study summary

Vaginismus is a sexual dysfunction characterized by involuntary contractions of the pelvic floor muscles that prevent vaginal penetration. This condition is often associated with intense fear, anxiety, and avoidance behaviors. Vaginismus can negatively impact not only sexual life but also gynecological examination processes, psychosocial well-being, and quality of life. In cases of vaginismus, where psychological components play a significant role, it is believed that virtual reality technology can reduce fear and avoidance behaviors by providing a safe and controlled environment. In particular, relaxing nature images and distracting visual content are expected to contribute to the treatment process by reducing anxiety levels. This study aims to evaluate the effects of virtual reality applications added to the standard approach in vaginismus treatment, and music therapy combined with virtual reality, on treatment success, pain level, anxiety level, and patient satisfaction.

Read the detailed description

Vaginismus is a sexual dysfunction characterized by involuntary contractions of the pelvic floor muscles that prevent vaginal penetration. This condition is often associated with intense fear, anxiety, and avoidance behaviors. Vaginismus can negatively impact not only sexual life but also gynecological examination processes, psychosocial well-being, and quality of life. Virtual reality (VR) technology has been used in many areas of healthcare in recent years for diagnostic, therapeutic, and rehabilitative purposes. In particular, VR applications have been shown to be effectively used in ophthalmology for visual rehabilitation, surgical training, amblyopia treatment, and patient adaptation processes. The clinical use of VR-based applications in amblyopia treatment and their inclusion in health insurance coverage supports the clinical applicability of this technology. VR technology is reported to have positive effects on attention redirection, relaxation, and anxiety reduction by creating controlled visual stimuli. The use of VR in gynecological procedures, pelvic examinations, and other invasive procedures has been shown to reduce pain and anxiety levels. Furthermore, VR applications have been reported to increase patient comfort and improve procedure tolerance in invasive urological procedures such as cystoscopy. In cases of vaginismus, where psychological components play a significant role, it is thought that virtual reality technology can reduce fear and avoidance behaviors by providing a safe and controlled environment. It is predicted that relaxing nature images, distracting visual content, and immersive experiences can contribute to the treatment process by reducing anxiety levels. The initiation of clinical trials evaluating the use of VR in vaginismus treatment in recent years shows that this approach is gaining increasing attention. Music therapy, on the other hand, is a non-pharmacological supportive method that has been shown to have positive effects on anxiety control, pain management, and emotional regulation. Studies in the literature report that the combined use of VR and music therapy can reduce symptoms in chronic pain, anxiety disorders, and stress-related conditions. This effect is thought to be related to autonomic nervous system regulation, multisensory integration, attention modulation, and emotional relaxation mechanisms. This study aims to evaluate the effects of VR applications added to the standard approach in vaginismus treatment, and music therapy combined with VR, on treatment success, pain level, anxiety level, and patient satisfaction.

02

Conditions studied

  • Vaginismus

Browse trials for

Keywords

  • vaginismus
  • transvaginal ultrasonography
  • immersive visual modulation
  • ambient music therapy
03

In context

Vaginismus

29 studies on the registry are indexed under Vaginismus; 9 are open to participants now.

This study's planned enrollment of 90 is above the median of 40 across 23 interventional studies indexed under Vaginismus.

Browse Vaginismus studies →

Lead sponsor

Demet Mutlu is the lead sponsor of 2 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 40 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female participants aged 20-40 years.
  • Diagnosis of Genito-Pelvic Pain/Penetration Disorder (GPPPD; vaginismus) according to criteria.
  • Failure to achieve vaginal intercourse despite previous standard care for vaginismus.
  • Previously evaluated by a gynecologist and/or a psychiatrist, clinical psychologist, or certified sexual therapist.
  • Scheduled to undergo transvaginal ultrasonography.
  • Able to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  • Active psychiatric disorder that may interfere with study participation.
  • Current pregnancy or previous childbirth.
  • Visual or hearing impairment preventing the use of the virtual reality device or ambient music intervention.
  • Pelvic anatomical abnormalities preventing transvaginal ultrasonography.
  • Concurrent participation in another interventional study for vaginismus.
  • Inability or unwillingness to provide written .
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Standart Care

    Participants receive standard care only.

    Behavioral: Standard Care

  • Experimental
    Standard Care + Immersive Visual Modulation (IVM)

    Participants receive standard care plus immersive virtual reality.

    Behavioral: Standard Care · Device: Immersive Visual Modulation (IVM)

  • Experimental
    Standard Care + IVM + Ambient Music Therapy (AMT)

    Participants receive standard care plus immersive virtual reality and ambient music therapy.

    Behavioral: Standard Care · Device: Immersive Visual Modulation (IVM) · Behavioral: Ambient Music Therapy (AMT)

Interventions

  • BehavioralStandard Care

    Participants receive standard care for vaginismus that had been provided before enrollment. No virtual reality or music intervention is administered during the transvaginal ultrasonography procedure.

  • DeviceImmersive Visual Modulation (IVM)

    Immersive Visual Modulation (IVM) is delivered using a virtual reality headset. Participants view standardized relaxing nature scenes beginning 15 minutes before transvaginal ultrasonography and continuing until the procedure is completed.

  • BehavioralAmbient Music Therapy (AMT)

    Participants listen to standardized instrumental ambient music with natural environmental sounds through over-ear headphones beginning 15 minutes before transvaginal ultrasonography and continuing until the procedure is completed.

06

What researchers measure

Primary outcomes

  1. Rate of successful completion of transvaginal ultrasonography (TVUS)

    The primary outcome is the rate of successful completion of the TVUS procedure. Successful completion is defined as complete insertion of the transvaginal ultrasound probe and completion of the examination without interruption due to pain, anxiety, fear, or involuntary pelvic floor muscle contraction. Results will be reported as the percentage of participants with successful TVUS completion in each intervention group.

    Time frame: Immediately after the TVUS procedure during the baseline study visit.

07

Study locations

1 site
  • Kayseri Private Erciyes Hospital
    Kayseri, Kayseri 38030, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No — Due to the personal data protection laws in our country, I cannot share patient information or data.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2026 (actual). Primary completion is estimated for Jul 2027, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2026
First posted
Jul 29, 2026
StartActual
Jul 16, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Jul 2027
Last update
Sep 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07734454
Lead sponsor
Demet Mutlu
Responsible party
Demet Mutlu (MD, Kayseri City Hospital) — Sponsor-investigator
First posted
Jul 29, 2026
Start date
Jul 16, 2026
Primary completion
Jul 2027 (estimated)
Completion
Jul 2027 (estimated)
Last update
Sep 23, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion